



## Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

September 21, 2023 8:05 PM EDT

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- [Verve Therapeutics](#), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:55 a.m. ET in New York.

A live webcast will be available in the investor section of the company's website at [www.vervetx.com](http://www.vervetx.com). The webcast will be archived for 30 days following the presentation.

### About Verve Therapeutics

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company's initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 and VERVE-102 are designed to permanently turn off the *PCSK9* gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) patients not at goal on oral therapy. VERVE-201 is designed to permanently turn off the *ANGPTL3* gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and ultimately to treat patients with refractory hypercholesterolemia. For more information, please visit [www.vervetx.com](http://www.vervetx.com).

### Investor Contact

Jen Robinson  
Verve Therapeutics, Inc.  
[jrobinson@vervetx.com](mailto:jrobinson@vervetx.com)

### Media Contact

Dan Budwick  
1AB Media  
[dan@1abmedia.com](mailto:dan@1abmedia.com)